title: Nicorandil suppresses urinary protein excretion and activates eNOS in Dahl salt-sensitive hypertensive rats.
abstract: BACKGROUND
  Hypertension is a risk factor common to both chronic kidney disease and cardiovascular disease. Nicorandil is widely used for the treatment of angina. We investigated the benefits of nicorandil with respect to renal dysfunction in Dahl salt-sensitive hypertensive (DS) rats.
  
  
  METHODS
  DS rats were fed a high-salt (HS) diet and nicorandil was administered via the drinking water. Blood pressure and renal function were measured for 4 weeks after starting the rats on the HS diet.
  
  
  RESULTS
  In rats fed the HS diet, renal dysfunction was manifested by an increase in urinary protein and N-acetyl-β-D-glucosaminidase excretion. Nicorandil ameliorated renal function with a concomitant reduction in urinary 8-hydroxy-2'-deoxyguanosine and an increase in urinary NOx. Significant upregulation of endothelial nitric oxide synthase (eNOS) expression and an increase in the eNOS dimer/monomer ratio (reduction of eNOS uncoupling) was demonstrated in glomeruli following nicorandil treatment. The blood pressure of DS rats was increased by salt loading; however, no significant change in blood pressure was observed with nicorandil treatment.
  
  
  CONCLUSIONS
  In DS rats fed a HS diet, nicorandil prevented the development of renal dysfunction, which was accompanied by an increase in eNOS expression in the kidneys.
authors: Product Research Department, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka, 412-8513, Japan.
authors: Yoshihito
authors: Y
authors: Tashiro
authors: Product Research Department, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka, 412-8513, Japan. yogoknj@chugai-pharm.co.jp.
authors: Kenji
authors: K
authors: Yogo
authors: Product Research Department, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka, 412-8513, Japan.
authors: Kenichi
authors: K
authors: Serizawa
authors: Product Research Department, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka, 412-8513, Japan.
authors: Koichi
authors: K
authors: Endo
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003839:Deoxyadenosines / Q000652:urine; D004789:Enzyme Activation / Q000187:drug effects; D007678:Kidney Glomerulus / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008297:Male; D020108:Nicorandil / Q000494:pharmacology / Q000627:therapeutic use*; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism*; D009589:Nitrogen Oxides / Q000652:urine; D011507:Proteinuria / Q000517:prevention & control*; D051381:Rats; D020303:Rats, Inbred Dahl; D017673:Sodium Chloride, Dietary / Q000008:administration & dosage; D015854:Up-Regulation / Q000187:drug effects
chemical_list: C436623:8-hydroxy-2'-deoxyadenosine; D000959:Antihypertensive Agents; D003839:Deoxyadenosines; D009589:Nitrogen Oxides; D017673:Sodium Chloride, Dietary; D020108:Nicorandil; D052250:Nitric Oxide Synthase Type III
keywords: NOx; Nicorandil; Oxidative stress; Salt-sensitive hypertensive nephropathy; eNOS